IL-35 Stimulation of CD39+ Regulatory T Cells Confers Protection against Collagen II-Induced Arthritis via the Production of IL-10

Irina Kochetkova, Sarah Golden, Kathryn Holderness, Gayle Callis and David W. Pascual

*This information is current as of December 15, 2017.*

**J Immunol** 2010; 184:7144-7153; Prepublished online 10 May 2010; doi: 10.4049/jimmunol.0902739

http://www.jimmunol.org/content/184/12/7144

---

**Why The JI?**

- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Speedy Publication!** 4 weeks from acceptance to publication

---

**References** This article cites 34 articles, 15 of which you can access for free at:

http://www.jimmunol.org/content/184/12/7144.full#ref-list-1

**Subscription** Information about subscribing to *The Journal of Immunology* is online at:

http://jimmunol.org/subscription

**Permissions** Submit copyright permission requests at:

http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at:

http://jimmunol.org/alerts

---

*The Journal of Immunology* is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852

Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved.

Print ISSN: 0022-1767 Online ISSN: 1550-6606.
IL-35 Stimulation of CD39+ Regulatory T Cells Confers Protection against Collagen II-Induced Arthritis via the Production of IL-10

Irina Kochetkova, Sarah Golden, Kathryn Holderness, Gayle Callis, and David W. Pascual

IL-35 is produced by regulatory T cells, and this novel cytokine can downregulate Th17 cell development and inhibit autoimmune inflammation. In this work, an rIL-35, as a single-chain fusion between murine IL-12p35 and EBV-induced gene 3, was expressed in yeast. This rIL-35 inhibited OVA-specific cellular and Ab responses in OVA-challenged recipients of DO11.10 CD4+ T cells. Likewise, IL-35 inhibited clinical manifestation of collagen-induced arthritis or could cease further disease exacerbation upon initiation of IL-35 treatment. Exogenous IL-35 treatments suppressed Th1 and Th17 cells and promoted CD39 expression by CD4+ T cells. Sorted CD25+CD39+CD4+ T cells from IL-35-treated mice produced IL-10 and, upon adoptive transfer, were sufficiently potent to inhibit subsequent development of inflammation in mice with collagen-induced arthritis, whereas sorted CD25+CD39– CD4+ T cells showed reduced potency. IL-35 treatments of IL-10−/− mice failed to induce protective CD39+CD4+ T cells, demonstrating the effector role of IL-10 by IL-35 immunosuppression.


Materials and Methods

Mice

BALB/c and C57BL/6 6- to 8-wk-old males (The Jackson Laboratory, Bar Harbor, ME, or Charles River Laboratories, Wilmington, MA), breeding colonies of DO11.10 TCR-transgenic mice, and IL-10−/− mice were maintained at Montana State University Animal Resources Center (Bozeman, MT) in individual ventilated cages under high-efficiency particulate absorbing-filtered barrier conditions. All procedures were compliant with institutional policies for animal health and well being.
rIL-35

rIL-35 was produced as a single polypeptide fusion between mouse IL-12p35 subunit and mouse EBI3 via a bovine elastin linker (VPGGVPGVG), as previously used for IL-12 (16). p35- elastin from pGT146mIL-12 (Invivogen, San Diego, CA) was amplified with primers containing 5’ EcoRI and 3’ SalI restriction sites. EB13 from pORF mIL-27 (Invivogen) was amplified with primers containing 5’ SalI and 3’ KpnI restriction sites. Fragments were cloned into Topo vectors (Invitrogen/Life Technologies, Carlsbad, CA), excised, and then a tripartite ligation was performed on p35-elastin EcoRI/Sall, EB13 SalI/KpnI, and the Pichia pastoris expression vector pPICZB EcoRI/KpnI. EcoRI primer bears an ATG initiation codon. Primers maintained an open reading frame between the two active components, as well as into the His-tag borne on the expression vector for protein purification. P. pastoris was transformed with a linearized construct via electroporation (Electro Cell Manipulator ECM630, BTX Harvard Apparatus, Holliston, MA). Yeast colonies were screened, and the final clone was grown following Easy Select Expression kit (Invitrogen).

For expressed protein purification, cells were disrupted by bead beating (BioSpec Products, Bartlesville, OK) and spun to remove debris, and filtered (0.45 μm) supernatant was applied to a Talon affinity resin column (BD Biosciences, San Jose, CA) per manufacturer’s instructions. The purified protein was probed by Western blot using anti-mouse mAb (R&D Systems, Minneapolis, MN), biotinylated polyclonal goat Abs to mouse IL-12 (R&D Systems), or anti-Histag mAb (Amersham Biosciences, Piscataway, NJ). The rIL-35 was determined to be 35% of the total protein and was subsequently dialyzed against PBS and stored at -80°C.

OVA-specific delayed-type hypersensitivity and Ab responses

CD4+ T cells were purified using Dynal Mouse CD4 Negative Isolation kit (Invitrogen) from DO11.10 spleens and lymph nodes (LNs). Purified CD4+T (3 × 105) cells were adoptively transferred to sex- and age-matched BALB/c mice (day 0). On day 1, all recipients were challenged with 100 μg OVA in IFA s.c., half of the recipients was treated i.p. with 0.75 μg IL-35 and half with 200 μl sterile PBS. Mice were treated with IL-35 or PBS daily until day 5, when a delayed-type hypersensitivity (DTH) test was performed, as previously described (17). DTH response was the difference in ear swelling between OVA- and PBS-challenged pinna.

On day 7, collected sera were evaluated by OVA-specific ELISA (17). Endpoint titers were expressed as the reciprocal logarithm of two for serum dilutions with an absorbance ≥0.1 above negative control.

OVA-specific T cell assays

DO11.10 CD4+ T cell recipients were challenged with OVA and treated with IL-35 or sterile PBS as described above. On day 7, mice were sacrificed, and splenic and LN CD4+ T cells were purified by negative isolation to >95% of purity. Purified CD4+ T cells were resuspended in complete medium, and 2.5 × 106 cells/well in 200 μl were restimulated with 1 μg/ml OVA323–339 peptide with syngenic irradiated (3000 rad) APCs. After 48 h, cells were pulsed with [3H]thymidine (0.5 μCi/well) for an additional 18 h. Cultured cells were harvested, and incorporated radioactivity was measured by scintillation counting. Stimulation index (SI) was calculated as (CPMstim – CPMunstim)/CPMunstim.

For cytokine production, purified CD4+ T cell cultures were restimulated for 4 d; supernatants were collected and analyzed by cytokine-specific ELISA.

CIA induction and IL-35 treatments

To induce CIA in C57BL/6 mice, lyophilized chicken collagen II (CII) (Chondrex, Redmond, WA) was solubilized in 0.05 M acetic acid at 2 mg/ml at 4°C 24 h prior to use, and then 100 μg chicken CII emulsified in CFA containing 4 mg/ml Mycobacterium tuberculosis (Chondrex) were injected s.c. in the tail 1.5–2 cm from the mouse body (Chondrex protocol; 15, 18).

Using this method, by day 35, nearly 100% of mice consistently showed clinical symptoms (15). Treatments with 0.75 μg IL-35 or sterile PBS were performed daily beginning day 21 post CIA challenge to the study termination. Mice were scored using a scale of 0–3 for each limb for a maximal total score of 12 (15): 0, no signs of inflammation; 1, mild redness or swelling of single digits; 2, significant swelling of ankle or wrist with erythema; and 3, severe swelling and erythema of multiple joints. Incidence of arthritis was the percent of animals with CIA in the group. Severity of the arthritis was the percent of animals with CIA in the group. Severity of the

![FIGURE 1.](http://www.jimmunol.org/Downloadedfromhttp://www.jimmunol.org)
disease was described by average clinical score. In addition, swelling in both knee joints and four paws was measured with an electronic digital caliper (World Precision Instruments, Sarasota, FL) in anesthetized mice on day 42 post CIA challenge, and cumulative swelling was calculated as a sum of all measurements per mouse.

Histopathological analysis of CIA

At study termination, joint sections were prepared, stained, and scored (15): 0, no changes; 1, synovial hyperplasia and mild inflammatory infiltration; 2, pannus formation with cartilage degeneration; and 3, heavy inflammatory infiltration, severe bone deformity and cartilage destruction. Cartilage degeneration was evaluated in toluidine blue-stained sections on a graded scale of 0–3: 0, no cartilage loss; 1, minimal chondrocytes and proteoglycan loss in superficial zone; 2, moderate chondrocytes and proteoglycan loss into middle zone above tidemark; and 3, severe cartilage degeneration through tidemark.

CII-specific Ab responses

Serum samples were collected from individual mice with CIA on days 21 and 35 (at peak of disease) postchallenge. Diluted sera were added to microtiter plates coated with 2 μg/ml ELISA-grade chicken CII (Chondrex) as previously described (15). Goat anti-mouse HRP-labeled IgG1, IgG2a, or IgG2b (Southern Biotechnology Associates, Birmingham, AL) were used as detecting Abs. Enzymatic reaction was developed with ABTS (Moss, Pasadena, MD). OD was read at 415 nm using ELx808 microplate reader (Bio-Tek Instruments, Winooski, VT). Endpoint titer represented a reciprocal logarithm of 2 for the serum dilution with an OD ≥0.1 above negative control.

CII-specific T cell assays

CD4+ T cells from axillary, popliteal, and inguinal LNs from IL-35– or PBS-treated C57BL/6 mice were purified (>95% purity) by magnetic bead separation using Dynal Mouse CD4 Negative Isolation kit (Invitrogen) at 42 d post CII challenge. The purified CD4+ T cells (10^6/ml) were restimulated with 50 μg/ml CII (T cell Proliferation Grade, Chondrex) in the presence of irradiated syngenic APCs. During the last 18 h of culture, [3H]thymidine (0.5 μCi/well) was added. Incorporated radioactivity in harvested samples was measured, and SI was calculated as above.

Flow cytometry

Individual spleens and LNs from PBS- or IL-35–treated mice were analyzed on day 28 post CIA challenge. Lymphocytes were fluorescently labeled with fluorochrome-conjugated mAbs: CD25 (BD Pharmingen, San Diego, CA), CD4, CD39, and FoxP3 (eBioscience). Fluorescence was acquired on an LSR II flow cytometer (BD Biosciences) using BD FACSDiva software, and samples were analyzed using FlowJo (Tree Star, Ashland, OR) software.

Adoptive transfer of CD39+ and CD39− CD4+ T cells

CIA was induced in C57BL/6 mice on day 0. On day 7, daily 0.75 μg treatments with IL-35 were initiated in separate groups of IL-10+/+ and IL-10−/− mice for 1 wk. On day 15 post CIA challenge, 10^6 CD39+ and CD39− CD4+ T cells, sorted, as described above, from IL-35– or PBS-treated mice were adoptively transferred to mice with CIA.

Adoptive transfer of CD25+ CD39+CD4+ and CD25−CD39−CD4+ T cells

CIA was induced in C57BL/6 mice on day 0 as described. Treatments with rIL-35 were initiated on day 7 in a separate group of C57BL/6 mice and treated daily for 1 wk. Purified total CD4+ T cells from IL-35–treated mice were stained with FITC–anti-CD4, Alexa Fluor 647–anti-CD39
(eBioscience), and PE-anti-CD25 (BD Pharmingen) and then sorted to CD25−CD39+ and CD25+CD39+ T cell subsets by BD FACSAria flow cytometer (BD Biosciences). On day 15 post CII challenge, mice were given i.v. $2 \times 10^5$ IL-35–induced, FACS-sorted CD25−CD39+ CD4+ or CD25+CD39+ CD4+ T cells (>95% purity). Mice were subsequently monitored for CIA development.

Statistics
Mann-Whitney U test was used for statistical analysis of DTH response, clinical scores, joint cumulative swelling, histology scores, and cartilage destruction. Fisher’s exact probability test was applied for incidence of CIA. One-way ANOVA and Student t test were performed to analyze T cell proliferation, flow cytometry, OVA-, CII-, and cytokine-specific ELISA data. Results were considered statistically significant if the p value was <0.05.

Results
Recombinant single-chain mouse IL-35
Mouse IL-35 was expressed as a single polypeptide between murine IL-12p35 and EBI3 genetically fused via an elastin linker (Fig. 1A) for expression in P. pastoris. The IL-35 was purified via its histag and recognized by Western blot using mAbs specific for histag or mouse EBI3, as well as by a polyclonal goat anti-mouse IL-12 Ab (Fig. 1A).

rIL-35 suppresses OVA-specific CD4+ T cell and Ab responses
To test the functional activity of rIL-35, a model of OVA-specific immunity was used. DO11.10 CD4+ T cells were sorted and transferred to BALB/c mice, challenged with OVA, and subsequently treated daily i.p with IL-35 or sterile PBS. On day 5, a DTH test was performed and ear thickness measured, revealing a 3-fold suppression to OVA-induced ear swelling by the IL-35–treated mice relative to PBS-treated mice (Fig. 1B). OVA-specific serum IgG2a and IgG2b Abs were significantly lessened by the IL-35 treatments (Fig. 1C), demonstrating that in vivo IL-35 treatments inhibit OVA-specific responses.

To investigate the impact of IL-35 upon OVA-specific Th cell responses, splenic and LN CD4+ T cells were sorted and evaluated in a T cell proliferation assay. Greater than 3-fold and ∼2-fold reductions in T cell proliferation by OVA-restimulated splenic and LN CD4+ T cells from IL-35–treated mice, respectively, were observed (Fig. 1D). Cytokine analysis of OVA-restimulated CD4+ T cells revealed ∼2.5-, 4-, and 8-fold reductions in IFN-γ, IL-6, and IL-17 production, respectively, by IL-35–treated mice relative to PBS-treated mice (Fig. 1E). IL-35 treatment resulted in significant suppression of IL-4 and IL-13 and concomitant increases in IL-10 and IL-9, but no changes in TGF-β were observed (Fig. 1E). These data demonstrate the immunosuppressive properties of IL-35 in an OVA-specific fashion.
IL-35 inhibits development of CIA in C57BL/6 mice

IL-35 was tested for its ability to suppress CIA. Arthritis can be induced in H-2b mice upon immunization with heterologous CII emulsified in CFA (18, 19), showing similar time of onset, clinical disease, and histopathology as CIA in DBA/1 mice (15). Starting 21 d post CIA induction, treatments with PBS or IL-35 were initiated daily until day 28. Only 10% of IL-35–treated mice showed clinical symptoms of arthritis, unlike PBS-dosed mice, which developed CIA over the expected time course with 100% incidence and average clinical score of ~6.5 (Fig 2A). Upon study termination, joint sections were stained with H&E, and some synovial hyperplasia was observed in median joint section of IL-35–treated mice, unlike the severely damaged joints obtained in PBS-treated animals (Fig. 2B). Sections stained with toluidine blue revealed minimal chondrocyte and proteoglycan loss in cartilage of IL-35–treated mice, whereas in control mice, the cartilage layer was irreversibly destroyed (Fig. 2B). On average, significantly lessened histopathological scores and cartilage losses were found in IL-35–treated mice when compared with PBS-treated mice (Fig. 2C). Thus, these experiments demonstrate that IL-35 is capable of suppressing the development of CIA.

IL-35 suppresses CII-specific Ab responses

To investigate the effect of exogenous IL-35 on CII-specific B cell responses, serum IgG1, IgG2a, and IgG2b anti-CII Ab levels from IL-35– or PBS-treated mice were evaluated pre- and posttreatments. CII-specific IgG1 and IgG2a Ab responses were significantly lower in IL-35–treated mice when compared with PBS-treated mice (Fig. 3A), whereas IgG2b Ab levels were not significantly affected (Fig. 3A). These data demonstrate that IL-35 can limit anti-CII Ab production during CIA.

IL-35 suppresses Th1 and Th17 cells in protected mice

To investigate mechanisms of protection by IL-35, CD4+ T cells purified from draining LNs of treated mice were restimulated with Ag and analyzed for cytokine production. IFN-γ and IL-17 levels were reduced 4- and 5-fold, respectively, by the IL-35 treatment (Fig. 3B). The observed intervention by IL-35 was not IL-4 or IL-13 dependent because IL-4 remained undetectable, and IL-13 levels were suppressed 5-fold when compared with control mice (Fig. 3B). Rather, IL-10 production was significantly augmented relative to the PBS-treated group. TGF-β production was unaffected by IL-35 treatment. Thus, IL-35 protects from CIA by suppressing the development of Th1 and Th17 cells. Importantly, this suppression is not accompanied by Th2 cell activation, but rather appears to be Treg cell dependent.

rIL-35 ceases the progression of established CIA

The potential of IL-35 to cease further development of CIA was tested. Arthritis was induced, as described above, and IL-35 or PBS treatments were initiated on day 35 post CII challenge; these mice received daily treatments for 4 d. The clinical disease by the IL-35–
treated mice did not worsen during and posttreatment until day 42, which showed an average clinical score of ~4. In contrast, the clinical disease exhibited by the PBS-treated mice continued to progress to a maximum score of ~7 by day 39 (Fig. 4A). Upon termination of the study, swelling of knee joints and paws in mice from both groups was measured and compared with age- and sex-matched naive C57BL/6 mice (Fig. 4B). The IL-35–treated mice showed lessened joint edema as compared with PBS-treated mice, further demonstrating that exogenous IL-35 is a potent inhibitor of autoimmune inflammation.

**IL-35 protects against CIA by the stimulation of regulatory CD39+CD4+ T cells**

Our previous studies suggest that increased CD39 expression by CD25+CD4+ T cells could be essential for conferring therapeutic intervention against CIA (15). To analyze the types of regulatory cells induced by IL-35 treatment, CD4+ T cells from spleens and pooled draining LNs of individual CII-challenged, IL-35–treated mice were analyzed for CD39, CD25, and FoxP3 expression. IL-35 treatment significantly increased the frequency of CD39+CD4+ T cells in spleens and LNs (Fig. 5A, 5B) with enhanced FoxP3 expression (Fig. 5C, 5D). Average frequencies of CD39+CD4+ T cells in spleens of IL-35– and PBS-treated mice were 38.6 ± 1.05% and 23.9 ± 1.44% of total CD4+ T cells, respectively (p < 0.001). Percent of FoxP3+CD39+CD4+ T cells in spleens of IL-35–treated mice was 27.8 ± 0.80% and PBS-treated mice 14.1 ± 1.43% (p < 0.001). Frequencies of CD39+CD4+ T cells in draining LNs were 21.3 ± 1.1% and 16.7 ± 0.72% in IL-35– and PBS-treated mice, respectively (p < 0.05). Expression of FoxP3 in LN CD39+CD4+ T cell subset was notably enhanced: 55.3 ± 4.35% in IL-35–treated mice versus 19.6 ± 3.41% in PBS-treated mice (p < 0.001) (Fig. 5E, 5F). As a subset of CD39+CD4+ T cells, both PBS- and IL-35–treated groups displayed similar CD25+CD4+ T cell frequencies (Fig. 5E). Notably, both CD25+CD4+ and CD25−CD4+ T cells demonstrated higher FoxP3 expression after IL-35 treatment (Fig. 5F). CII-restimulated, cell-sorted total CD39+CD4+ and CD39−CD4+ T cells from PBS-treated and from protected mice revealed that IL-35 treatment supports proliferation of CD39+CD4+ T cells (Fig. 5G).

**In vivo IL-35 promotes IL-10 production**

Because FoxP3 associated with both Treg and CD39+CD4+ T cells and implicated the stimulation of a mixed regulatory T cell response, the cytokine profiles of sorted CD39+CD4+ and CD39−CD4+ T cells from C57BL/6 and IL-10−/− mice treated with IL-35 or sterile PBS were investigated. Groups of mice were treated daily with IL-35 or PBS for 7 d and then sorted for their CD4+ T cell subsets. CD39+CD4+ T cells from IL-35–treated C57BL/6 and IL-10−/− mice produced significantly less IFN-γ in comparison with PBS-treated C57BL/6 and IL-10−/− mice (Fig. 6A). IL-35 treatment did not alter IL-17 production by C57BL/6, but enhanced 5-fold IL-17 production by IL-10−/−CD39−CD4+ T cells (Fig. 6A). IL-4 and IL-13 production by CD39−CD4+ T cells was suppressed in both PBS- and IL-35–treated IL-10−/− mice and netted a 2-fold reduction in IL-4 by C57BL/6 mice, but IL-35 treatment augmented 4-fold IL-10 production by C57BL/6 CD39+CD4+ T cells (Fig. 6A).

**FIGURE 6.** Cytokine profiles of CD39− and CD39+CD4+ T cells from IL-10+/+ and IL-10−/− mice after IL-35 or PBS treatment. Naive mice were given PBS or IL-35 for 7 d, and then splenic and LN CD4+ T cells were sorted for CD39− and CD39+CD4+ T cell subsets (>95% purity). Each (10⁶ cells/ml) was stimulated with plate-bound anti-CD3 and soluble anti-CD28 mAbs for 4 d. Mean concentration of cytokine in supernatant ± SEM from triplicate cultures is shown. A, CD39−CD4+ T cells’ cytokine profile. *p < 0.001; **p < 0.005; ***p < 0.01. B, CD39+CD4+ T cells’ cytokine profile. *p < 0.001; **p < 0.01; ***p < 0.05 between IL-10+/+ and IL-10−/− mice.
Evaluation of CD39+CD4+ T cells from C57BL/6 and IL-10−/− mice revealed minimal to no IFN-γ responses (Fig. 6B). IL-35–treated C57BL/6 mice showed marked IL-17 suppression by CD39+CD4+ T cells, unlike IL-10−/− CD39+CD4+ T cells that produced elevated levels of IL-17 and modestly enhanced IL-9 (Fig. 6B). CD39+CD4+ T cells from IL-35–treated C57BL/6 mice produced >10-fold more IL-10, but IL-4, IL-9, and IL-13 remained unaffected. Thus, these studies reveal in vivo IL-35 treatment stimulates IL-10 production.

IL-35–induced CD39+CD4+ T cells protect against CIA

To ascertain whether IL-35–induced CD39+CD4+ T cells are protective against CIA, adoptive transfer studies were performed. CIA was induced in C57BL/6 mice, and separate groups of C57BL/6 and IL-10−/− mice were treated with IL-35 daily for CD39+CD4+ T cell induction (Fig. 7A). On day 15, CII-challenged mice received sorted CD39−CD4+ or CD39+CD4+ T cells from IL-35–treated mice (Fig. 7A). CD39−CD4+ T cells from IL-35–treated C57BL/6 mice failed to protect against CIA (Fig. 7B). In contrast, CD39+CD4+ T cells from IL-35–treated C57BL/6 mice significantly reduced incidence and clinical scores by recipients (Fig. 7C), mimicking protective efficacy obtained with IL-35 (Fig. 2A). Notably, CD39+CD4+ T cells from IL-35–treated IL-10−/− mice failed to confer protection against CIA, much like PBS-treated C57BL/6 mice (Fig. 7C), supporting the notion that IL-10 plays an important effector role in IL-35–mediated immune suppression. Upon termination of study, CD4+ T cell cytokine analysis revealed significant IFN-γ and IL-17 reductions in recipients of C57BL/6 CD39+CD4+ T cells (Fig. 7E), unlike recipients given IL-10−/− CD39+CD4+ T cells, in which IFN-γ and IL-17 levels were similar to recipients given PBS-treated C57BL/6 CD39+CD4+ T cells (Fig. 7E). IL-10 was produced only by protected mice, the recipients of

**FIGURE 7.** IL-35–induced CD39+CD4+ T cells from IL-10+/+, not IL-10−/− mice, confer protection to CIA. A, Scheme for adoptive transfer experiment. CIA was induced in recipient groups on day 0. On days 7–14, IL-35 was given to donor mice. On day 15 postinduction of CIA, recipient mice were adoptively transferred with 10^6 of cell-sorted CD39+ or CD39−CD4+ T cells (93% purity) from IL-10+/+ or IL-10−/− mice. B, Severity of arthritis and incidence of the disease in recipients of CD39−CD4+ T cells are shown. C, Severity of arthritis and incidence of the disease in recipients of CD39+CD4+ T cells are shown. Data represent mean clinical score per group of 10 mice ± SEM. *p < 0.001; **p < 0.05. One of three experiments is depicted. CD4+ T cell cytokine production by recipients given CD39−CD4+ T cells (D) and by recipients given CD39+CD4+ T cells (E) is shown. LN cells were restimulated with CII for 4 d, as previously described. *p < 0.001; **p < 0.005; ***p < 0.05.
CD39+CD4+ from IL-35-treated C57BL/6 mice (Fig. 7E). Recipients of IL-35-treated C57BL/6 CD39+CD4+ T cells produced less IFN-γ, although no significant changes in IL-17 production were observed (Fig. 7D).

**IL-35–induced CD25+CD39+CD4+ T cells are potent regulatory cells for CIA**

Based on the finding that regulatory CD39+CD4+ T cells include both CD25+ and CD25− phenotypic subsets, additional analyses were conducted to test the protective properties of these T cell subsets. As described above, CIA was induced in C57BL/6 mice on day 0, and on day 7, IL-35 treatments were initiated in a separate group of C57BL/6 mice. On day 15, CIA-challenged mice were adoptively transferred with cell-sorted CD25+CD39+CD4+ or CD25−CD39−CD4+ T cells from the IL-35-treated mice, and mice were monitored for development of clinical disease until day 39. Recipients of CD25+CD39+CD4+ T cells did not show any clinical symptoms during the observation period. In contrast, 40% of the CD25−CD39−CD4+ T cell recipients developed delayed clinical disease ~9 d later than in the PBS-treated control group, although these recipient mice did exhibit significantly lessened clinical disease (p = 0.006; Table I). The maximum score for the PBS-treated mice was 10, whereas the CD25+CD39+CD4+ T cell recipients showed a clinical score of 6. These results indicate that both regulatory CD39+CD4+T cells are capable of suppressing CIA, but it is evident that CD25−CD39−CD4+ T cells show the greatest potency in suppressing CIA.

**Discussion**

The IL-12 family members EBI3 and IL-12p35 together form a novel anti-inflammatory cytokine, IL-35 (2, 7, 8). Characterization of EBI3 revealed that it has a dual role, having either inflammatory or anti-inflammatory properties. As a heterodimer with IL-27p28 produced by APCs, EBI3 promotes Th1 cell differentiation from naive T cells and, hence, inflammation (1, 3, 4). It has been shown that EBI3 mRNA and protein expression are restricted to Treg cells, but not effector T cells (Teff cells). EBI3−/− Treg cells fail to suppress Teff cell proliferation in vitro, and these are unable to cease inflammatory bowel disease (7). Similarly, EBI3−p35−Fc fusion protein promotes development of Treg cells and suppresses Th17 cells (8). To further elucidate IL-35’s protective mechanisms, rIL-35 was made as a single-chain polypeptide of IL-12p35 with EBI3. Consistent with previous findings, rIL-35's properties. To examine its therapeutic potential, in this study, IL-35 treatments began 21 d post CII challenge at disease onset. Using this regimen, only 10% of C57BL/6 mice developed CIA, evidenced by the lack of infiltration and cartilage destruction in joints accompanied by suppression of CII-specific Th1 and Th17 cells. Typically, CIA induces elevated IFN-γ relative to naïve controls (15, 21).

Th17 cells have been shown to be essential for development of autoimmune inflammation (22, 23). In the arthritis models, IL-17 promotes synovial infiltration with polymorphonuclear leukocytes and production of proinflammatory cytokines, IL-1- and IL-6 (24–26). It can also directly stimulate bone destruction via induction of the receptor activator of NF-κB ligand expression on CD4+ T cells and osteoclastogenesis (27). Consistent with an earlier report (8), IL-17 and IL-6 production by CD4+ T cells are suppressed by the IL-35 treatments supporting the notion that IL-35 can regulate Th17 cells, as recently made evident by the enhanced expression of IL-17, IL-22, and transcription factor RORγt, by CD4+ T cells from EBI3−/− mice (28).

The anti-inflammatory impact by IL-35 manifested as enhanced IL-10 production by CD4+ T cells from treated mice without impacting IL-9 production. It has been shown that IL-10−/− mice are more susceptible to CIA characterized by earlier onset and more severe clinical disease than IL-10+/+ mice (29). Our results demonstrated the importance of IL-10, particularly IL-10−producing regulatory CD4+ T cells, in CIA suppression by IL-35. Our findings regarding IL-10–relevance add to the recent in vitro findings that IL-35–mediated suppression of T cell proliferation is IL-10–dependent, and cell–cell contact between Teff and Treg cells is not required (30). Notably, IL-35 was capable of delaying

<table>
<thead>
<tr>
<th>Treatment</th>
<th>CIA/Total</th>
<th>Day Onset</th>
<th>Maximum Score</th>
<th>Average Score</th>
<th>Cumulative Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>10/10</td>
<td>26 ± 1.47</td>
<td>10</td>
<td>6.8 ± 0.57</td>
<td>42.5 ± 5.82</td>
</tr>
<tr>
<td>CD25+CD39+</td>
<td>0/5</td>
<td>NA</td>
<td>0</td>
<td>0*</td>
<td>0***</td>
</tr>
<tr>
<td>CD25−CD39−</td>
<td>2/5</td>
<td>35 ± 2.02</td>
<td>6</td>
<td>2.0 ± 1.26**</td>
<td>5.2 ± 3.87****</td>
</tr>
</tbody>
</table>

*Exogenous IL-35–induced CD25+CD39+CD4+ and CD25−CD39−CD4+ T cells were adoptively transferred to mice (2 × 10^7 cells/mouse) with induced CIA on day 15 post CII challenge.

1Number of mice with CIA/total in a group for 39 d post CII challenge.

2Mean day ± SEM of first symptoms onset in diseased mice.

3Maximum individual mouse score in group in entire observation period.

4Average clinical score per group on day 39 postchallenge calculated as sum of individual scores divided by the number of mice in group ± SEM.

5Cumulative scores calculated as all scores during the period of observation divided by number of mice in each group.

*p = 0.003 as compared with PBS group; **p = 0.01 as compared with PBS group; ***p = 0.003 as compared with PBS group; ****p = 0.006 as compared with PBS group.
progression of already established CIA if treatments were started on day 35 post CII challenge. This observation is consistent with the IL-10–dependent anti-inflammatory mechanism of suppression by IL-35. Recently, it was shown that IL-10–secreting Treg cells adoptively transferred on day 28 postinduction of CIA were protective against autoimmunity (31).

Importantly, our study showed that two Treg cell subsets are induced in vivo by exogenous IL-35. IL-35 treatment subsequent CIA development resulted in the stimulation of FoxP3 expression by splenic CD25<sup>+</sup>CD39<sup>+</sup> and CD25<sup>+</sup>CD39<sup>+</sup>CD4<sup>+</sup> T cells, and CD39 was only significantly induced by LN FoxP3<sup>+</sup>CD4<sup>+</sup> T cells. Purified CD39<sup>+</sup>CD4<sup>+</sup> T cells from PBS-dosed mice with CIA responded to CII restimulation, evident by their proliferation, and CD39<sup>+</sup>CD4<sup>+</sup> T cells were unresponsive to CII. Purified CD39<sup>+</sup>CD4<sup>+</sup> T cells from naive C57BL/6 mice treated with IL-35 showed dramatic reductions in vivo, by exogenous IL-35. IL-35 treatment subsequent CIA development of at least two regulatory CD4<sup>+</sup> T cell subsets induced by IL-35, as evident by their expression of CD39 and CD25, and both subsets, CD25<sup>+</sup>CD39<sup>+</sup>CD4<sup>+</sup> and CD25<sup>+</sup>CD39<sup>+</sup>CD4<sup>+</sup> T cells, are potent against autoimmune arthritis. Thus, these studies suggest that IL-35 treatments can stimulate alternative regulatory subsets to dampen autoimmunity.

Acknowledgments

We thank Nancy Kommers for assistance in preparing this manuscript.

Disclosures

The authors have no financial conflicts of interest.

References


